News Releases | Upcoming Events | Webcast/Presentation Archive

View printer-friendly version << Back

Masimo Pledges to Increase Investment in Research & Development and Infrastructure, in Response to Today’s Moratorium on the Medical Device Tax

12/18/15

IRVINE, Calif.--(BUSINESS WIRE)--Dec. 18, 2015-- Masimo (NASDAQ: MASI), the global innovator of noninvasive patient monitoring technologies, announced today that it will increase investment in infrastructure and research and development in response to the moratorium on the Medical Device Tax.

For years, the United States has led the world in life-saving medical innovations. Unfortunately, the Medical Device Tax of 2013 became an impediment to innovation that springs from start-ups, and many established companies curtailed their investments in research and development and reduced their workforces to pay the new revenue tax.

“We applaud the bipartisan efforts of Congress and the administration to suspend the medical device tax for two years,” said Joe Kiani, Chairman and CEO of Masimo. “This two-year moratorium will allow us to immediately begin to increase our investment in our infrastructure and research and development.”

@MasimoInnovates | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive open architecture patient monitoring and connectivity platform designed to speed the pace of innovation and reduce the cost of care. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7 wearable patient monitor and the MightySat fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com.

Source: Masimo

Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com